{"type":"trials","record":{"id":42086,"source_id":"clinicaltrials-gov","external_id":"NCT04480463","title":"A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)","brief_summary":"Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting vision. The current standard of care for patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy, which prevents or slows down the growth of the abnormal blood vessels. SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an anti-VEGF drug. The study aims to prove equivalence of SCD411 to Eylea in adults with wet AMD, and will look at safety, tolerance, effectiveness, immune response and the movement of the drug through the body.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Sam Chun Dang Pharm. Co. Ltd.","enrollment":576,"countries":["United States","Australia","Bulgaria","Czechia","Hungary","India","Israel","Japan","Latvia","Poland","Russia","Slovakia","South Korea","Spain"],"start_date":"2020-08-13","completion_date":"2022-09-08","last_update_date":"2023-10-10","source_url":"https://clinicaltrials.gov/study/NCT04480463","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Aflibercept","organization":"Sam Chun Dang Pharm. Co. Ltd.","interventions":["SCD411","Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change From Baseline in BCVA (Best Corrected Visual Acuity) — Baseline to Week 8","Change From Baseline in BCVA (Best Corrected Visual Acuity) — Baseline to Week 52","Percentage of Subjects With Anti-SCD411 Antibodies — Baseline, Weeks 4, 8, 20, 36 and 52"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":true},"controlled_terms":["Wet Age-related Macular Degeneration","Neovascular Age-related Macular Degeneration","SCD411","Aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04480463","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-08-13 to 2022-09-08","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.918Z","intervention":["SCD411","Aflibercept"],"participants":576,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change From Baseline in BCVA (Best Corrected Visual Acuity) — Baseline to Week 8","Change From Baseline in BCVA (Best Corrected Visual Acuity) — Baseline to Week 52","Percentage of Subjects With Anti-SCD411 Antibodies — Baseline, Weeks 4, 8, 20, 36 and 52"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42086","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}